Stifel analysts maintained their Buy rating on Insmed shares (NASDAQ:INSM) and increased the price target from $88.00 to $97.00. According to InvestingPro data, the stock has delivered an impressive ...

Brensocatib, if approved, would be the first available treatment specifically targeting bronchiectasis, a chronic lung disease that currently has no FDA-approved therapies in the U.S. The drug is also ...

Roger Adsett, Chief Operating Officer of Insmed Inc. (NASDAQ:INSM), recently sold a substantial amount of company stock. According to an SEC filing, Adsett sold a total of 43,975 shares on February 10 ...

uhb.nhs.uk Background Non-cystic fibrosis bronchiectasis is characterised by irreversibly dilated bronchi usually associated with chronic sputum production, bacterial colonisation of the lower ...

Along with two large-scale M&A deals signed in recent weeks - the takeovers of antibody-drug conjugate (ADC) company ImmunoGen and central nervous system specialist Cerevel for $10.1 billion and $ ...

The drug inhibits a novel target to reduce levels of inorganic pyrophosphate (PPi), a key metabolite central to the ... the first approved therapy for bronchiectasis in the US.

BEND, Ore. (KTVZ)– It’s what drivers and business owners are calling a headache. Traffic backed up on Greenwood Avenue in downtown Bend, a week… ...

The curious case of Cody's big mouth: General Hospital Two Scoops for the week of February 3, 2025 The curious case of Cody's big mouth: General Hospital Two Scoops for the week of February 3, 2025 4d ...

Rights Mar 17, 2011 Mar 18, 2011 Jul 29, 2010 Rights ratio: 3 share for every 5 held at a price of Rs 103.0 ...